R A Huddart

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. pmc The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/07/011
    Clare Moynihan
    Institute of Cancer Research, London, UK
    Trials 13:228. 2012
  2. pmc Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004)
    Robert A Huddart
    Institute of Cancer Research
    Int J Radiat Oncol Biol Phys 87:261-9. 2013
  3. pmc Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011)
    Sangeetha Paramasivan
    School of Social and Community Medicine, University of Bristol, 39 Canynge Hall, Whatley Road, Bristol BS8 2PS, UK
    Trials 12:78. 2011
  4. ncbi request reprint Improving treatment outcomes in testicular cancer: strategies to reduce treatment related morbidity
    R A Huddart
    Academic Unit of Radiotherapy and Oncology, The Institute of Cancer Research and The Royal Marsden NHS Trust, Downs Road, Sutton, Surrey, UK
    BJU Int 92:524-6. 2003
  5. pmc Survival from testicular cancer in England and Wales up to 2001
    R A Huddart
    The Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 99:S83-5. 2008
  6. ncbi request reprint 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group
    Robert A Huddart
    Academic Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, UK
    J Clin Oncol 25:3090-5. 2007
  7. pmc Fertility, gonadal and sexual function in survivors of testicular cancer
    R A Huddart
    Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 93:200-7. 2005
  8. ncbi request reprint Recent advances in the treatment of testicular cancer
    Robert A Huddart
    The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, The Academic Unit of Radiotherapy and Oncology, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Expert Rev Anticancer Ther 5:123-38. 2005
  9. ncbi request reprint Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone
    H Patterson
    Academic Radiotherapy Unit, Institute of Cancer Research and the Royal Marsden NHS Trust, 15 Cotswold Road, Belmont, Sutton, SM2 5NG, Surrey, UK
    Radiother Oncol 59:5-11. 2001
  10. ncbi request reprint Evaluating the effect of reducing the high-dose volume on the toxicity of radiotherapy in the treatment of bladder cancer
    S A Mangar
    Academic Radiotherapy, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Clin Oncol (R Coll Radiol) 18:466-73. 2006

Detail Information

Publications60

  1. pmc The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/07/011
    Clare Moynihan
    Institute of Cancer Research, London, UK
    Trials 13:228. 2012
    ..The aim was to illuminate problems in the context of randomization...
  2. pmc Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004)
    Robert A Huddart
    Institute of Cancer Research
    Int J Radiat Oncol Biol Phys 87:261-9. 2013
    ..To test whether reducing radiation dose to uninvolved bladder while maintaining dose to the tumor would reduce side effects without impairing local control in the treatment of muscle-invasive bladder cancer...
  3. pmc Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011)
    Sangeetha Paramasivan
    School of Social and Community Medicine, University of Bristol, 39 Canynge Hall, Whatley Road, Bristol BS8 2PS, UK
    Trials 12:78. 2011
    ....
  4. ncbi request reprint Improving treatment outcomes in testicular cancer: strategies to reduce treatment related morbidity
    R A Huddart
    Academic Unit of Radiotherapy and Oncology, The Institute of Cancer Research and The Royal Marsden NHS Trust, Downs Road, Sutton, Surrey, UK
    BJU Int 92:524-6. 2003
  5. pmc Survival from testicular cancer in England and Wales up to 2001
    R A Huddart
    The Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 99:S83-5. 2008
  6. ncbi request reprint 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group
    Robert A Huddart
    Academic Radiotherapy, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, UK
    J Clin Oncol 25:3090-5. 2007
    ....
  7. pmc Fertility, gonadal and sexual function in survivors of testicular cancer
    R A Huddart
    Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 93:200-7. 2005
    ..Most patients retain their fertility, but the risk of infertility is likely to be increased by chemotherapy. Screening for gonadal dysfunction should be considered in the follow-up of testicular cancer survivors...
  8. ncbi request reprint Recent advances in the treatment of testicular cancer
    Robert A Huddart
    The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, The Academic Unit of Radiotherapy and Oncology, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Expert Rev Anticancer Ther 5:123-38. 2005
    ..In particular, the use of radiotherapy in Stage I seminoma and the need for adjuvant therapy in Stage I nonseminoma are being re-examined. It is anticipated that advances in imaging and prognostic factors will facilitate this process...
  9. ncbi request reprint Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone
    H Patterson
    Academic Radiotherapy Unit, Institute of Cancer Research and the Royal Marsden NHS Trust, 15 Cotswold Road, Belmont, Sutton, SM2 5NG, Surrey, UK
    Radiother Oncol 59:5-11. 2001
    ..Confirmation would require a phase III randomized comparison...
  10. ncbi request reprint Evaluating the effect of reducing the high-dose volume on the toxicity of radiotherapy in the treatment of bladder cancer
    S A Mangar
    Academic Radiotherapy, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Clin Oncol (R Coll Radiol) 18:466-73. 2006
    ..The aims of this study were to establish the efficacy and compare the late toxicity between (1) a two-phase technique limiting the high-dose area and (2) a conventional single-phase radiotherapy to the whole bladder...
  11. ncbi request reprint Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy
    A S N Jackson
    The Academic Department of Radiotherapy, Royal Marsden Hospital, Sutton, Surrey, UK
    Clin Oncol (R Coll Radiol) 17:167-71. 2005
    ..To evaluate the prognostic significance of magnetic resonance imaging (MRI) tumour stage in clinically localised prostate cancer...
  12. ncbi request reprint Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer
    M Shahidi
    Academic Department of Radiotherapy and Oncology, The Royal Marsden NHS Trust, The Institute of Cancer Research, Sutton, UK
    Clin Oncol (R Coll Radiol) 13:291-5. 2001
    ..Serum testosterone levels are restored to normal levels in the majority of patients, with a compensatory increase in serum levels of LH...
  13. doi request reprint Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma
    A Horwich
    Division of Radiotherapy and Imaging, The Institute of Cancer Research and Urological Oncology Unit, The Royal Marsden NHS Trust, Sutton, UK
    Ann Oncol 24:2104-7. 2013
    ..Extended field radiotherapy is a standard of care for low volume stage II testicular seminoma. We hypothesized that neoadjuvant carboplatin might reduce the recurrence risk...
  14. pmc Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects
    D P Dearnaley
    Academic Department of Radiotherapy and Oncology, Institute of Cancer Research, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 92:488-98. 2005
    ..Data from this randomised pilot study informed the Data Monitoring Committee of the Medical Research Council RT 01 Trial and the two studies will be combined in subsequent meta-analysis...
  15. ncbi request reprint Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors
    J A Christian
    Academic Department of Radiotherapy and Oncology, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    J Clin Oncol 21:871-7. 2003
    ..This study assesses the outcome of patients with poor-prognosis nonseminomatous germ cell tumors (NSGCT) treated with CBOP/BEP...
  16. ncbi request reprint Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer
    R Venkitaraman
    Academic Uro oncology Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK
    J Med Imaging Radiat Oncol 53:241-7. 2009
    ..Whole-body MRI and radionuclide bone scintigraphy have similar specificity and sensitivity and may be used as complementary investigations to detect skeletal metastases from prostate cancer...
  17. doi request reprint Does magnetic resonance imaging of the spine have a role in the staging of prostate cancer?
    R Venkitaraman
    Academic Uro oncology Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
    Clin Oncol (R Coll Radiol) 21:39-42. 2009
    ..The aim of this study was to compare MRI spine with radionuclide bone scan in detecting spinal metastases for staging prostate cancer patients...
  18. ncbi request reprint Cardiovascular disease as a long-term complication of treatment for testicular cancer
    R A Huddart
    Academic Unit of Radiotherapy and Oncology, Royal Marsden NHS Trust and Institute of Cancer Research, Downs Rd, Sutton, Surrey SM2 5PT, United Kingdom
    J Clin Oncol 21:1513-23. 2003
    ..To assess the risk of cardiovascular morbidity and cardiac risk factors in long-term survivors of testicular cancer according to treatment received...
  19. pmc The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours
    A M Cook
    Academic Department of Radiotherapy and Oncology, The Royal Marsden NHS Trust, and Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Br J Cancer 85:1624-6. 2001
    ..3% (95% confidence limits (CI) 2.4-16.1). These data suggest that avascular necrosis is an uncommon but significant complication of chemotherapy including steroids as anti-emetics...
  20. ncbi request reprint Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours
    J M O'Sullivan
    Academic Unit of Radiotherapy and Clinical Oncology, The Institute of Cancer Research, Royal Marsden NHS Trust, Sutton, UK
    Ann Oncol 14:91-6. 2003
    ..Postulated risk factors include cumulative bleomycin dose, reduced glomerular filtration rate (GFR), raised creatinine, older age and supplemental oxygen exposure...
  21. ncbi request reprint Management of early prostate cancer
    A Horwich
    Department of Clinical Oncology Academic Unit, Royal Marsden Hospital, Sutton, UK
    Ann Oncol 13:83-7. 2002
  22. doi request reprint Genomic gain and over expression of CCL2 correlate with vascular invasion in stage I non-seminomatous testicular germ-cell tumours
    D C Gilbert
    Molecular Cytogenetics, Section of Molecular Carcinogenesis, The Institute of Cancer Research, Sutton, Surrey, UK
    Int J Androl 34:e114-21; discussion e121. 2011
    ..This work gives further insight into the mechanisms involved in invasion in this tumour type, which may ultimately have implications for the management of patients with stage I disease...
  23. ncbi request reprint Distribution of lymph nodes in men with prostatic adenocarcinoma and lymphadenopathy at presentation: a retrospective radiological review and implications for prostate and pelvis radiotherapy
    A S N Jackson
    Academic Department of Radiotherapy and Oncology, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK
    Clin Oncol (R Coll Radiol) 18:109-16. 2006
    ..This will help to define which nodal groups should be treated during the pelvic radiotherapy of patients with less advanced disease...
  24. doi request reprint Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents
    D C Gilbert
    Molecular Cytogenetics, Section of Molecular Carcinogenesis, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    J Pathol 217:94-102. 2009
    ..Our observations support a role for CXCL12/CXCR4 in the adult germ cell population and demonstrate pathological function in germ cell tumour development and metastasis that may have clinical utility...
  25. ncbi request reprint Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy
    Duncan C Gilbert
    Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    BJU Int 98:67-9. 2006
    ..To estimate the rate of relapse in men with stage I nonseminomatous germ cell tumours (NSGCT) of the testis treated with one cycle of chemotherapy instead of the usual two cycles...
  26. pmc The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer
    A M Cook
    The Royal Marsden NHS Trust and Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 82:1952-7. 2000
    ..Ninety per cent of patients who achieved a marker response had done so by 8 weeks. Monitoring of tumour markers in patients with advanced bladder cancer can help predict the response to chemotherapy...
  27. ncbi request reprint ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumors (NSGCT)
    R A Huddart
    Institute of Cancer Research, 15 Cotswolds Rd, Sutton Surrey, SM7 1DN, UK
    Ann Oncol 16:i37-9. 2005
  28. doi request reprint Pentoxifylline to treat radiation proctitis: a small and inconclusive randomised trial
    R Venkitaraman
    Academic Urology Unit, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    Clin Oncol (R Coll Radiol) 20:288-92. 2008
    ..However, a modest benefit cannot be excluded and larger randomised placebo-controlled trials with longer durations of pentoxifylline treatment may be justified...
  29. ncbi request reprint Detection of occult spinal cord compression with magnetic resonance imaging of the spine
    R Venkitaraman
    Academic Urology Unit, Royal Marsden Hospital, Sutton, Surrey, UK
    Clin Oncol (R Coll Radiol) 19:528-31. 2007
    ..The aim of this investigation was to determine the role of magnetic resonance imaging of the spine in detecting SCC or occult SCC in patients with metastatic prostate cancer with no functional neurological deficit (FND)...
  30. ncbi request reprint Preliminary results of a phase I dose escalation clinical trial using focused ultrasound in the treatment of localised tumours
    A G Visioli
    Joint Department of Physics, Institute of Cancer Research, Royal Marsden NHS Trust, Sutton, Surrey SM2 5PT, UK
    Eur J Ultrasound 9:11-8. 1999
    ..This would appear to be the first time that treatment has been given without sedation or anaesthesia...
  31. ncbi request reprint Accelerated chemotherapy in the treatment of urothelial cancer
    R A Huddart
    Academic Unit of Radiotherapy and Oncology, Royal Marsden Hospital, NHS Trust, Sutton, UK
    Clin Oncol (R Coll Radiol) 13:279-83. 2001
    ..Accelerated regimens may be useful in situations were it is necessary to administer chemotherapy over a short time (e.g. as part of combined modality treatment)...
  32. ncbi request reprint Challenges in treating patients with Down's syndrome and testicular cancer with chemotherapy and radiotherapy: The Royal Marsden experience
    S Hafeez
    Radiotherapy Department, Royal Marsden Hospital NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Clin Oncol (R Coll Radiol) 19:135-42. 2007
    ..We aimed to identify and discuss management challenges in the treatment of these patients with chemotherapy and radiotherapy and report their clinical outcome...
  33. ncbi request reprint A discussion of the biology of testicular cancer and current concepts in the management of stage I and bilateral disease
    J Coffey
    Academic Urology Unit, Royal Marsden Hospital, Sutton, UK
    Clin Oncol (R Coll Radiol) 17:441-7. 2005
    ..The second primary was managed conservatively. The rationale and outcome of this approach was presented, along with a discussion of the management of early stage TGCTs and the genetics of familial and bilateral disease...
  34. ncbi request reprint Technological advances in radiotherapy for the treatment of localised prostate cancer
    Stephen A Mangar
    Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton SM2 5NG, UK
    Eur J Cancer 41:908-21. 2005
    ....
  35. ncbi request reprint Adjuvant chemotherapy for high-risk low-stage germ-cell tumours
    Alan Horwich
    The Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Trust and The Institute of Cancer Research, Sutton, Surrey UK
    Curr Opin Urol 12:431-4. 2002
    ..To review the assessment and management of early germ-cell tumours...
  36. pmc Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse
    N J van As
    Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK
    Br J Cancer 98:1894-902. 2008
    ..Furthermore, this should enable future trials to address specific issues around follow-up giving meaningful and useful results...
  37. pmc Testicular microlithiasis as a familial risk factor for testicular germ cell tumour
    J Coffey
    Testicular Cancer Genetics Team, Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 97:1701-6. 2007
    ..We suggest that TM is an alternative manifestation of a TGCT susceptibility allele...
  38. ncbi request reprint The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397)
    David P Dearnaley
    Institute of Cancer Research and Royal Marsden Hospitals, Sutton, UK
    Radiother Oncol 83:31-41. 2007
    ..Conformal radiotherapy (CFRT) raises the possibility that radiotherapy doses can be increased and long-term efficacy outcomes improved, with safety an important consideration...
  39. doi request reprint Multiple newly identified loci associated with prostate cancer susceptibility
    Rosalind A Eeles
    The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
    Nat Genet 40:316-21. 2008
    ..7 x 10(-29)). We confirmed previous reports of common loci associated with prostate cancer at 8q24 and 17q. Moreover, we found that three of the newly identified loci contain candidate susceptibility genes: MSMB, LMTK2 and KLK3...
  40. ncbi request reprint Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management
    Mehdi Shahidi
    Academic Department of Radiotherapy and Oncology, The Royal Marsden NHS Trust, Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    Cancer 95:520-30. 2002
    ..The time-course of recurrence has implications for the duration of follow-up. This study was undertaken to assess the risk and time-course of recurrence and to identify patients at higher risk of late recurrence...
  41. ncbi request reprint Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer
    Vedang Murthy
    Academic Unit of Radiotherapy and Oncology, and Department of Computing and Information, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Surrey, UK
    BJU Int 97:476-9. 2006
    ..To prospectively evaluate the time-course of recovery of serum testosterone levels after a short course of luteinizing hormone-releasing hormone analogue (LHRHa) and radical radiotherapy to the prostate...
  42. pmc Identification of new genetic risk factors for prostate cancer
    Michelle Guy
    Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
    Asian J Androl 11:49-55. 2009
    ..Follow-up validation studies, as well as studies to explore the psychological implications of genetic profile testing, will be vital prior to roll out into healthcare...
  43. ncbi request reprint Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses
    William F Hendry
    Academic Department of Urology, The Royal Marsden National Health Service Trust and Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Cancer 94:1668-76. 2002
    ..A retrospective analysis was undertaken to define the outcome in these two groups of patients...
  44. pmc Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer
    Clare Turnbull
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 42:604-7. 2010
    ..Finally, we identified a locus on chromosome 9 (rs755383, OR=1.37, P=1.12x10(-23)), containing the sex determination gene DMRT1, which has been linked to teratoma susceptibility in mice...
  45. pmc A genome-wide association study of testicular germ cell tumor
    Elizabeth A Rapley
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 41:807-10. 2009
    ..05-3.19), P = 10(-31)). KITLG, encoding the ligand for the receptor tyrosine kinase KIT, which has previously been implicated in the pathogenesis of TGCT and the biology of germ cells, may explain the association on chromosome 12...
  46. pmc High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone
    J M O'Sullivan
    Unit of Academic Radiotherapy and Clinical Oncology, Royal Marsden NHS Trust, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 86:1715-20. 2002
    ..The main toxicity is thrombocytopaenia, which is short lasting. A statistically significant activity/prostate specific antigen response was seen. We have now commenced a Phase II trial to further evaluate response rates...
  47. pmc Microsatellite instability in human testicular germ cell tumours
    R A Huddart
    Section of Molecular Carcinogenesis, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 72:642-5. 1995
    ..This pattern of instability is distinct from that reported in colorectal cancer and other cancers that have a high level of alterations in dinucleotide repeats...
  48. pmc Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer
    C C Parker
    Academic Department of Radiotherapy and Oncology, The Royal Marsden NHS Trust and Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 86:686-91. 2002
    ..The nomogram illustrates the results of multivariate analysis in a visually-striking way, and facilitates comparisons with other treatment methods...
  49. ncbi request reprint The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours
    Ramachandran Venkitaraman
    Academic Urology Unit, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK
    BJU Int 100:30-2. 2007
    ....
  50. pmc Identification of seven new prostate cancer susceptibility loci through a genome-wide association study
    Rosalind A Eeles
    The Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 41:1116-21. 2009
    ..In addition to replicating previous associations, we identified seven new prostate cancer susceptibility loci on chromosomes 2, 4, 8, 11 and 22 (with P = 1.6 x 10(-8) to P = 2.7 x 10(-33))...
  51. ncbi request reprint Efficacy of low-dose dexamethasone in castration-refractory prostate cancer
    Ramachandran Venkitaraman
    Academic Urology Unit, Royal Marsden Hospital, Sutton, Surrey, UK
    BJU Int 101:440-3. 2008
    ....
  52. doi request reprint Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer
    Jennifer L Glendenning
    Urology Unit, The Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom
    Cancer 116:2322-31. 2010
    ..The authors report a cross-sectional study of the long-term effects of chemotherapy (C) on neurologic function and development of Raynaud phenomenon...
  53. doi request reprint Clinical implications of introducing a new PSA assay
    Ramachandran Venkitaraman
    Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Int Urol Nephrol 40:657-61. 2008
    ..The availability of two assays in the same laboratory provided an opportunity to audit the clinical implications of the interassay variation in PSA levels...
  54. ncbi request reprint Outcome of early detection and radiotherapy for occult spinal cord compression
    Ramachandran Venkitaraman
    Academic Urology Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK
    Radiother Oncol 85:469-72. 2007
    ..Thus MRI surveillance for SCC may be important for prostate cancer patients with bone metastases...
  55. ncbi request reprint Variability of bladder filling in patients receiving radical radiotherapy to the prostate
    Una M O'Doherty
    Radiotherapy Department, Royal Marsden NHS Foundation Trust, Sutton, UK
    Radiother Oncol 79:335-40. 2006
    ..This study investigated patients' ability to consistently maintain a full bladder throughout planning and treatment before (Study 1) and after (Study 2) the introduction of a patient information sheet...
  56. ncbi request reprint Neuron-specific enolase expression in multiple myeloma
    Ricky A Sharma
    Department of Radiotherapy, Royal Marsden Hospital, London, UK
    Lancet Oncol 7:960. 2006
  57. ncbi request reprint Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer
    Alison J Birtle
    BJU Int 97:1348; author reply 1348-50. 2006
  58. ncbi request reprint Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cance
    Gordon J Rustin
    Mount Vernon Cancer Centre, Northwood, Middlesex HA62RN, United Kingdom
    J Clin Oncol 25:1310-5. 2007
    ..A randomized trial of two versus five computed tomography (CT) scans was performed to determine whether the number of scans influenced the proportion of patients relapsing with intermediate- or poor-prognosis disease at relapse...
  59. ncbi request reprint Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
    David P Dearnaley
    Institute of Cancer Research and Royal Marsden Hospitals, Sutton and London, UK
    Lancet Oncol 8:475-87. 2007
    ..We aimed to present the first analyses of effectiveness from the MRC RT01 randomised controlled trial...
  60. ncbi request reprint Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)
    Malcolm D Mason
    Velindre Hospital, Department of Oncology and Palliative Medicine, School of Medicine, Cardiff University, Cardiff, UK
    J Natl Cancer Inst 99:765-76. 2007
    ..Adjuvant bisphosphonate treatment improves outcomes of patients with bone metastasis-negative breast cancer, but the effects of bisphosphonates on bone metastases in prostate cancer are not known...